Orphazyme gets another annual report extension approved
Biotech firm Orphazyme is pushing back the release of its annual report for 2021 once again, allowing the company to proceed with the ongoing in-court restructuring.
by marketwire, translated by daniel pedersen
Biotech company Orphazyme has been granted another new deadline for the release of its full-year 2021 report, the company has announced in a press release on Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme files for delisting in US
For subscribers
